KR102590740B1 - 항-대리 경쇄 항체 - Google Patents

항-대리 경쇄 항체 Download PDF

Info

Publication number
KR102590740B1
KR102590740B1 KR1020177024616A KR20177024616A KR102590740B1 KR 102590740 B1 KR102590740 B1 KR 102590740B1 KR 1020177024616 A KR1020177024616 A KR 1020177024616A KR 20177024616 A KR20177024616 A KR 20177024616A KR 102590740 B1 KR102590740 B1 KR 102590740B1
Authority
KR
South Korea
Prior art keywords
ser
leu
thr
gly
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177024616A
Other languages
English (en)
Korean (ko)
Other versions
KR20170120120A (ko
Inventor
로렌스 호로위츠
Original Assignee
칠드런스 헬스 케어 디/비/에이 칠드런스 미네소타
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 칠드런스 헬스 케어 디/비/에이 칠드런스 미네소타 filed Critical 칠드런스 헬스 케어 디/비/에이 칠드런스 미네소타
Publication of KR20170120120A publication Critical patent/KR20170120120A/ko
Application granted granted Critical
Publication of KR102590740B1 publication Critical patent/KR102590740B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020177024616A 2015-02-02 2016-01-27 항-대리 경쇄 항체 Active KR102590740B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562111018P 2015-02-02 2015-02-02
US62/111,018 2015-02-02
PCT/US2016/015166 WO2016126488A1 (en) 2015-02-02 2016-01-27 Anti-surrogate light chain antibodies

Publications (2)

Publication Number Publication Date
KR20170120120A KR20170120120A (ko) 2017-10-30
KR102590740B1 true KR102590740B1 (ko) 2023-10-18

Family

ID=56564528

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177024616A Active KR102590740B1 (ko) 2015-02-02 2016-01-27 항-대리 경쇄 항체

Country Status (10)

Country Link
US (1) US10858448B2 (enExample)
EP (2) EP3253793A4 (enExample)
JP (1) JP2018507254A (enExample)
KR (1) KR102590740B1 (enExample)
CN (1) CN107849123A (enExample)
AU (1) AU2016215676B2 (enExample)
CA (2) CA2975346A1 (enExample)
HK (1) HK1247941A1 (enExample)
IL (1) IL253579A0 (enExample)
WO (1) WO2016126488A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016126488A1 (en) 2015-02-02 2016-08-11 Sea Lane Biotechnologies, Llc Anti-surrogate light chain antibodies
WO2016127043A1 (en) 2015-02-05 2016-08-11 Stc.Unm Anti-pre-bcr antagonists and methods
AU2017366739B2 (en) 2016-12-02 2023-11-23 Angeles Therapeutics, Inc. Synthetic immune receptors and methods of use thereof
US11407828B2 (en) * 2019-02-01 2022-08-09 Novarock Biotherapeutics, Ltd. Anti-CLauDiN 18 antibodies and methods of use thereof
CA3138550A1 (en) * 2019-04-30 2020-11-05 Target Discovery Merger Sub II, LLC Cancer associated antibody compositions and methods of use
CN112300282A (zh) * 2020-11-03 2021-02-02 南京北恒生物科技有限公司 靶向cd7的人源化抗体及其用途
IL305188A (en) * 2021-02-16 2023-10-01 Childrens Health Care D/B/A Childrens Minnesota Methods for treating B-ALL by administering a pre-BCR complex antagonist
JP2025534161A (ja) * 2022-10-04 2025-10-14 ミンク セラピューティクス， インコーポレイテッド 線維芽細胞活性化タンパク質（ｆａｐ）ｃａｒインバリアントナチュラルキラーｔ細胞及びその使用
WO2025212740A1 (en) * 2024-04-03 2025-10-09 Mink Therapeutics, Inc. Composition and methods for treating colorectal cancer liver metastasis (crc liver mets)

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2010A (en) 1841-03-18 Machine foe
US62950A (en) 1867-03-19 Improvement in apparatus foe the manufacture of vinegar
JPS60222842A (ja) 1984-04-19 1985-11-07 Fuji Photo Film Co Ltd ハロゲン化銀写真乳剤およびその製造方法
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US5182205A (en) 1986-11-27 1993-01-26 Hoffmann-La Roche Inc. Nucleotide sequences which are selectively expressed in pre-B cells and probes therefor
DE3789138T2 (de) 1986-11-27 1994-05-26 Hoffmann La Roche Nukleotid-Sequenzen, die selektiv exprimiert sind in pre-B-Zellen und Sonden zu diesem Zweck.
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9206318D0 (en) 1992-03-24 1992-05-06 Cambridge Antibody Tech Binding substances
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
WO1992018619A1 (en) 1991-04-10 1992-10-29 The Scripps Research Institute Heterodimeric receptor libraries using phagemids
US5871907A (en) 1991-05-15 1999-02-16 Medical Research Council Methods for producing members of specific binding pairs
US6225447B1 (en) 1991-05-15 2001-05-01 Cambridge Antibody Technology Ltd. Methods for producing members of specific binding pairs
US6492160B1 (en) 1991-05-15 2002-12-10 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
US7067284B1 (en) 1992-01-27 2006-06-27 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
US5233409A (en) 1992-02-25 1993-08-03 Schwab Karl W Color analysis of organic constituents in sedimentary rocks for thermal maturity
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9225453D0 (en) 1992-12-04 1993-01-27 Medical Res Council Binding proteins
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US6326155B1 (en) 1995-03-20 2001-12-04 Dyax Corp. Engineering affinity ligands for macromolecules
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
US6706484B1 (en) 1995-08-18 2004-03-16 Morphosys Ag Protein/(poly)peptide libraries
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
GB9712818D0 (en) 1996-07-08 1997-08-20 Cambridge Antibody Tech Labelling and selection of specific binding molecules
WO1999006541A1 (fr) * 1997-07-29 1999-02-11 Sumitomo Electric Industries, Ltd. Anticorps du recepteur des cellules pre-b non humaines
JPH11133028A (ja) * 1997-10-29 1999-05-21 Sumitomo Electric Ind Ltd 抗ヒトプレｂ細胞レセプター抗体
US20030215453A1 (en) * 2002-05-14 2003-11-20 Dedera Douglas A. Methods of therapy and diagnosis using immunotargeting of cells expressing VpreB1 protein
GB2377997A (en) * 2001-07-24 2003-01-29 Bookham Technology Plc Connection of a non-perpendicular optical fibre to an optical device
JP4602614B2 (ja) 2001-09-26 2010-12-22 アイシン精機株式会社 自動車用ドア
ATE536376T1 (de) * 2003-12-23 2011-12-15 Crucell Holland Bv Humanes bindungsmolekül gegen cd1a
AU2007303572A1 (en) 2006-10-02 2008-04-10 Sea Lane Biotechnologies, Llc Design and construction of diverse synthetic peptide and polypeptide libraries
JP5779350B2 (ja) 2007-03-27 2015-09-16 シー レーン バイオテクノロジーズ， エルエルシー 抗体代替軽鎖配列を含む構築物およびライブラリー
CN102149727A (zh) 2008-07-11 2011-08-10 航道生物技术有限责任公司 包含抗体替代卡帕轻链序列的构建体和文库
EP3205723A1 (en) * 2009-06-26 2017-08-16 i2 Pharmaceuticals, Inc. Expression of surrogate light chains
IL269565B2 (en) * 2011-01-06 2024-06-01 Dyax Corp Plasma kallikrein binding proteins
WO2016126488A1 (en) 2015-02-02 2016-08-11 Sea Lane Biotechnologies, Llc Anti-surrogate light chain antibodies
WO2016127043A1 (en) * 2015-02-05 2016-08-11 Stc.Unm Anti-pre-bcr antagonists and methods

Also Published As

Publication number Publication date
US10858448B2 (en) 2020-12-08
KR20170120120A (ko) 2017-10-30
CA3185253A1 (en) 2016-08-11
EP3253793A1 (en) 2017-12-13
WO2016126488A1 (en) 2016-08-11
AU2016215676A1 (en) 2017-08-10
AU2016215676B2 (en) 2021-12-02
CN107849123A (zh) 2018-03-27
EP4177267A1 (en) 2023-05-10
US20180265594A1 (en) 2018-09-20
CA2975346A1 (en) 2016-08-11
EP3253793A4 (en) 2018-11-14
JP2018507254A (ja) 2018-03-15
HK1247941A1 (zh) 2018-10-05
IL253579A0 (en) 2017-09-28

Similar Documents

Publication Publication Date Title
KR102590740B1 (ko) 항-대리 경쇄 항체
JP6591964B2 (ja) Ｉｃｏｓｌへの治療上の標的特異的ｖｎａｒドメインの単離
KR101540822B1 (ko) 항체 대용물 경쇄 서열을 포함하는 구축물 및 라이브러리
JP5522405B2 (ja) 安定な多価抗体
JP7663977B2 (ja) 抗ｐｄ―ｌ１抗体およびその用途
KR102802736B1 (ko) Ilt7 결합 분자 및 이의 사용 방법
HK1244014A1 (zh) Cd3/cd38 t细胞重靶向异源二聚体免疫球蛋白及其生产方法
RS50830B (sr) Sintetički domeni imunoglobulina sa vezujućim svojstvima izgrađenim u područjima molekula različitim od komplementarno određujućih područja
US20100062950A1 (en) Constructs and libraries comprising antibody surrogate kappa light chain sequences
WO2009142460A2 (en) Antibody-peptide fused synergibody
KR20200143730A (ko) 3가 삼중 특이성 항체 구조물
HK40090806A (en) Anti-surrogate light chain antibodies
US20100233167A1 (en) Chain reaction creating oligomers from repeat units of binding molecules
US20110245100A1 (en) Generation of antibodies to an epitope of interest
CN117677637A (zh) 抗犬cd20抗体
HK1159132A (en) Constructs and libraries comprising antibody surrogate kappa light chain sequences
HK1183309A (en) Novel lowered affinity antibodies and methods of making the same

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

A302 Request for accelerated examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D17-exm-PA0302

St.27 status event code: A-1-2-D10-D16-exm-PA0302

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601